

## BRONCHIAL PROVOCATION USING INHALED MANNITOL – A PHASE 3 TRIAL OF ADULT & PEDIATRIC ASTHMATICS & NON-ASTHMATICS

J D Brannan<sup>1</sup>, S D Anderson<sup>1</sup>, R Freed-Martens<sup>1</sup> and the Aridol Study Group

<sup>1</sup>*Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, NSW 2050*

We performed a Phase 3 study to investigate the safety and efficacy of dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness in adults and children (n=592, age 6-83yrs, median 33.9 yr, median BMI 24.6, 53.7% F). For the test, FEV<sub>1</sub> is measured 60 sec after inhaling increasing doses of mannitol (e.g. 0,5,10,20,40,80,160,160,160mg) (Pharmaxis Ltd, Australia) from a dry powder inhaler (Plastiap, Italy) to a cumulative dose of 635mg (Anderson SD et al, AJRCCM 1997;156:758). A positive test is a fall of  $\geq 15\%$  in FEV<sub>1</sub> (PD<sub>15</sub>FEV<sub>1</sub>). 105 non-asthmatic (56M;49F) and 487 with a clinical diagnosis of asthma (218M;260F) based on history, spirometry, medications and response to hypertonic (4.5%) saline performed the test. The median FEV<sub>1</sub> % predicted was 95% (Mean $\pm$ SD 95.3% $\pm$ 14.5). Of the 592, 434 were taking beta<sub>2</sub>-agonists, 166 were taking inhaled corticosteroids (ICS), 235 were taking combination therapy, 123 were taking none of these medications. ICS and combination therapy were withheld for 12hrs and short acting beta<sub>2</sub> agonists for 8hrs before testing. 290 asthmatics were positive to mannitol with a median PD<sub>15</sub> 148 mg (range: 0.2-627.8), 197 were negative. Five non-asthmatic subjects were positive to mannitol, 100 were negative. For the 197 asthmatic subjects negative to mannitol 85% were taking either ICS alone or in combination with a long acting beta<sub>2</sub> agonist. Of the 290 with a positive test 71% were taking these medications. There were no serious adverse events during or after challenge. The efficacy and safety of bronchial provocation with mannitol was demonstrated in non-asthmatic and clinically diagnosed asthmatic adults and children.

Supported by Pharmaxis Ltd

**Key Words:** mannitol, asthma, bronchial provocation, adults, children